Results 21 to 30 of about 2,141 (223)
Survival and Prognostic Factors of 215 Post-Transplant Lymphoproliferative Disorders After Solid Organ Transplantations in a Finnish Nationwide Population-Based Study Over 30 Years. [PDF]
Hematol OncolABSTRACT Post‐transplant lymphoproliferative disorder (PTLD) is a rare, dreaded complication of organ transplantation with major clinical challenges. We conducted a nationwide population‐based study of all solid organ transplant (SOT) recipients (n = 6555), both adults and children, over a 30‐year period in Finland.
Friman TK +11 more
europepmc +2 more sources
BMC Infectious Diseases, 2022 Background Patients with Lyme borreliosis (LB) may report persisting non-specific symptoms such as fatigue, widespread musculoskeletal pain or cognitive difficulties.
Laurence Geebelen +12 more
doaj +1 more source
Myositis Autoantibodies in Patients with Suspected Post-Treatment Lyme Disease Syndrome
Life, 2023 Most patients suffering from Lyme disease are effectively treated with antibiotics. In some patients, however, problems persist for a long time despite appropriate therapy.
Kristyna Sloupenska +10 more
doaj +1 more source
A Distinct Microbiome Signature in Posttreatment Lyme Disease Patients
mBio, 2020 Lyme disease is the most common vector-borne disease in the United States, with an estimated incidence of 300,000 infections annually. Antibiotic intervention cures Lyme disease in the majority of cases; however, 10 to 20% of patients develop ...
Madeleine Morrissette +10 more
doaj +1 more source
PLoS ONE, 2021 BackgroundPersistent symptoms attributed to presumed tick-bite exposure constitute an unresolved medical controversy. We evaluated whether Swedish adults who met the criteria for post-treatment Lyme disease syndrome (PTLDS) exhibited characteristics ...
Kenneth Nilsson +8 more
doaj +1 more source
Treatment of PTLD with Rituximab or Chemotherapy [PDF]
American Journal of Transplantation, 2006 Information regarding treatment of post-transplant lymphoproliferative disease (PTLD) beyond reduction in immunosuppression (RI) is limited. We retrospectively evaluated patients receiving rituximab and/or chemotherapy for PTLD for response, time to treatment failure (TTF) and overall survival (OS). Thirty-five patients met inclusion criteria.
R L, Elstrom +10 more
openaire +2 more sources
Case Reports in Transplantation, 2020 The posttransplant lymphoproliferative disorders (PTLDs) are a heterogeneous group of neoplasms that have wide variety of clinical and histological presentations. The management of PTLDs is challenging due to variety of involvement sites and histological
S. Gandhi +5 more
doaj +1 more source
Chronic Diseases and Translational Medicine, 2023 Lyme disease is the most common vector‐borne illness in the United States and has been causing significant morbidity since its discovery in 1977. It is well‐documented that about 10% of patients properly treated with antibiotics never fully recover, but ...
Natalie A. Bai, Christie S. Richardson
doaj +1 more source
Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2018 Post-transplant lymphoproliferative disorders (PTLDs) are serious, life-threatening complications of transplantation, which represent a heterogeneous group of lymphoproliferative diseases and show a spectrum of clinical, morphologic, and molecular genetic features ranging from reactive polyclonal lesions to frank lymphomas.
openaire +2 more sources
Frontiers in Medicine, 2017 BackgroundThe increased incidence and geographic expansion of Lyme disease has made it the most common vector-borne infection in North America. Posttreatment Lyme disease syndrome (PTLDS) represents a subset of patients who remain ill following standard ...
Alison W. Rebman +6 more
doaj +1 more source